PABD - ETF AI Analysis
Top Page
iShares Paris-Aligned Climate MSCI World ex USA ETF (PABD)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the past month, indicating positive recent momentum.
Leading Holdings Performing Well
Several of the largest positions, including ASML, HSBC, Schneider Electric, ABB, and major Canadian and Australian banks, have delivered strong year-to-date results that support the fund’s overall performance.
Low Expense Ratio
The fund charges a relatively low management fee, which helps investors keep more of their returns over time.
Negative Factors
Heavy Financial Sector Exposure
A large portion of the portfolio is invested in financial companies, which can make the fund more sensitive to changes in interest rates and banking conditions.
Underperforming Health Care Giant
One of the major health care holdings, Roche, has shown weak year-to-date performance, which can drag on the fund’s returns if the trend continues.
Limited U.S. Market Coverage
Because this is a world ex-USA fund, it offers only modest exposure to U.S. stocks, which may cause it to lag if the U.S. market outperforms other regions.
PABD vs. SPDR S&P 500 ETF (SPY)
AUM317.93M
RegionDeveloped Markets
Expense Ratio0.12%
Beta0.77
IssueriShares
Inception DateJan 17, 2024
Dividend Yield2.58%
Asset ClassEquity
Index TrackedMSCI World ex USA Climate Paris Aligned Benchmark Extended Select Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,785
30 Day Avg. Volume8,588
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
77.97Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering415
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PABD Summary
PABD is an ETF that follows the MSCI World ex USA Climate Paris Aligned Index, focusing on companies outside the U.S. that are working to cut carbon emissions and support the goals of the Paris climate agreement. It holds a wide mix of international stocks, including well-known names like ASML Holding and Novartis, across sectors such as financials, healthcare, and technology. Someone might invest in PABD to get global diversification while supporting more climate-friendly businesses. A key risk is that its value can go up and down with global stock markets and climate-focused stocks may underperform broader indexes.
How much will it cost me?The iShares Paris-Aligned Climate MSCI World ex USA ETF (PABD) has an expense ratio of 0.12%, meaning you’ll pay $1.20 per year for every $1,000 invested. This is lower than average because it’s passively managed, tracking an index rather than relying on active stock-picking strategies.
What would affect this ETF?Positive drivers for PABD include the growing global focus on sustainability and climate action, which could benefit companies aligned with the Paris Agreement goals. However, economic slowdowns in developed markets outside the U.S. or regulatory changes affecting key sectors like financials and technology could negatively impact the ETF's performance.
PABD Top 10 Holdings
PABD leans heavily on non-U.S. financials and industrials, with big global banks like HSBC, Royal Bank of Canada, TD, and Commonwealth Bank providing much of the recent lift as they trend higher together. On the industrial and climate-solutions side, Schneider Electric and ABB are powering ahead, fitting the fund’s low‑carbon theme and adding momentum. ASML is also rising, giving the ETF a tech edge. The main drag comes from Roche, where performance has been mixed to lagging, slightly offsetting strength in steadier pharma names like Novartis and AstraZeneca. Overall, it’s a developed-markets ex-U.S. play with a clear tilt toward climate-focused industrials and global banks.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.90% | $9.28M | €503.99B | 110.43% | 76 Outperform | |
| Novartis AG | 1.44% | $4.60M | CHF206.95B | 24.69% | 80 Outperform | |
| Royal Bank Of Canada | 1.40% | $4.48M | $254.17B | 51.05% | 75 Outperform | |
| ABB Ltd | 1.40% | $4.47M | CHF147.66B | 81.83% | 78 Outperform | |
| HSBC Holdings | 1.36% | $4.36M | £226.79B | 55.42% | 80 Outperform | |
| Schneider Electric | 1.33% | $4.26M | €153.54B | 26.79% | 62 Neutral | |
| Roche Holding AG | 1.31% | $4.20M | $323.93B | 32.62% | 73 Outperform | |
| AstraZeneca | 1.31% | $4.18M | $282.15B | 30.31% | 80 Outperform | |
| Toronto Dominion Bank | 0.99% | $3.17M | $181.61B | 70.08% | 74 Outperform | |
| Advantest | 0.97% | $3.12M | ¥20.85T | 311.03% | 75 Outperform |
PABD Technical Analysis
Positive
―
Price Trends
65.95
Positive
66.43
Positive
64.01
Positive
Market Momentum
0.59
Negative
57.30
Neutral
82.26
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PABD, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 67.83, equal to the 50-day MA of 65.95, and equal to the 200-day MA of 64.01, indicating a bullish trend. The MACD of 0.59 indicates Negative momentum. The RSI at 57.30 is Neutral, neither overbought nor oversold. The STOCH value of 82.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PABD.
PABD Peer Comparison
Comparison Results
Performance Comparison
PABD
iShares Paris-Aligned Climate MSCI World ex USA ETF
68.68
12.40
22.03%
LCTD
BlackRock World ex U.S. Carbon Transition Readiness ETF
―
―
―
SNSR
Global X Internet of Things ETF
―
―
―
FINX
Global X Fintech Etf
―
―
―
IFGL
iShares International Developed Real Estate ETF
―
―
―
FEDM
FlexShares ESG & Climate Developed Markets ex-US Core Index Fund ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents